Cellromax Science Co., Ltd. Logo

Cellromax Science Co., Ltd.

Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.

471820 | KO

Overview

Corporate Details

ISIN(s):
KR7471820001
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 구성로 357 D동 710호 (청덕동, 용인테크노밸리), 용인시

Description

Cellromax Science Co., Ltd. is a company specializing in the research, development, and manufacturing of health-related products. Its portfolio is centered on three key areas: health functional foods, derma-cosmetics, and over-the-counter (OTC) pharmaceuticals. The company leverages scientific research and high-quality, naturally derived ingredients to create unique and effective products. Its development philosophy emphasizes optimized formulas and specialized prescriptions designed to support consumer health, skin vitality, and overall well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-17 00:00
임시주주총회결과
Korean HTML 7.4 KB
2025-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean HTML 5.4 KB
2025-12-16 00:00
현금ㆍ현물배당결정
Korean HTML 9.2 KB
2025-09-12 00:00
현금ㆍ현물배당결정 (분기배당)
Korean HTML 8.1 KB
2025-09-12 00:00
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean HTML 5.5 KB
2025-09-01 00:00
감자완료
Korean HTML 8.9 KB
2025-08-27 00:00
반기보고서 (2025.06)
Korean HTML 1.2 MB
2025-08-13 00:00
[기재정정]주요사항보고서(감자결정)
Korean HTML 22.5 KB
2025-08-12 00:00
[기재정정]전환청구권행사 (제1회차)
Korean HTML 11.8 KB
2025-07-23 00:00
임시주주총회결과
Korean HTML 5.6 KB
2025-07-22 00:00
전환청구권행사 (제1회차)
Korean HTML 8.7 KB
2025-07-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.0 KB
2025-07-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.2 KB
2025-07-09 00:00
현금ㆍ현물배당결정 (분기배당)
Korean HTML 8.8 KB
2025-07-09 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean HTML 35.5 KB

Automate Your Workflow. Get a real-time feed of all Cellromax Science Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellromax Science Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellromax Science Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.